Clinical Trial Update: Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

View source ↗

Summary

Completed study evaluating whole-body imaging with Indium-111 labeled exendin-4 to visualize insulin-secreting tumors in insulinoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperinsulinism
• Hypoglycemia
• Insulinoma

Drugs mentioned

• Indium-111-exendin-4 imaging agent (indium-111-labeled exendin-4)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Hyperinsulinism, Hypoglycemia | Status: COMPLETED